The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Hyzon Motors Inc. fka Decarbonization Plus Acquisition Corporation Class Period: February 9, 2021 and September 27, 2021 Lead Plaintiff Motion Deadline: November 29, 2021 SECURITIES FRAUD To learn more, visit Bristol-Myers Squibb Company Class: Investors who received Contingent Value ...

The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.

Hyzon Motors Inc. (NasdaqGS: HYZN, HYZNW) f/k/a Decarbonization Plus Acquisition Corporation (NasdaqGS: DCRB, DCRBU, DCRBW)
Class Period: February 9, 2021 and September 27, 2021
Lead Plaintiff Motion Deadline: November 29, 2021
SECURITIES FRAUD
To learn more, visit https://kclasslaw.com/cases/securities/nasdaqgs-hyzn/

Bristol-Myers Squibb Company (BMY)
Class: Investors who received Contingent Value Rights ("CVRs") (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers' acquisition of Celgene on November 20, 2019
Lead Plaintiff Motion Deadline: December 6, 2021
MISLEADING PROSPECTUS
To learn more, visit https://kclasslaw.com/cases/securities/nyse-bmy/

D-MARKET Electronic Services & Trading (d/b/a "Hepsiburada") (HEPS)
Class Period: purchase of shares issued either in or after the July 2021 Initial Public Offering
Lead Plaintiff Motion Deadline: December 20, 2021
MISLEADING PROSPECTUS
To learn more, visit https://kclasslaw.com/cases/securities/nasdaqgs-heps/

Höegh LNG Partners LP (HMLP)
Class Period: August 22, 2019 and July 27, 2021
Lead Plaintiff Motion Deadline: December 27, 2021
SECURITIES FRAUD
To learn more, visit https://kclasslaw.com/cases/securities/nyse-hmlp/

Shareholders who purchased shares in these companies during the dates listed are encouraged to contact us via the case links above, by calling toll-free at 1-833-835-1495 or by email (dk@kclasslaw.com).

If you wish to serve as lead plaintiff with the goal of overseeing the litigation to obtain a fair and just resolution, you must petition the Court on or before the deadlines provided above.

Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Kuznicki Law PLLC
Daniel Kuznicki, Esq.
445 Central Avenue, Suite 344
Cedarhurst, NY 11516
Email: dk@kclasslaw.com
Phone: (347) 696-1134
Cell: (347) 690-0692
Fax: (347) 348-0967
https://kclasslaw.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

FDA Approves New KYPROLIS® Combination Regimen With DARZALEX FASPRO® and dexamethasone For Patients With Multiple Myeloma At First Or Subsequent Relapse

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the expansion of the KYPROLIS ® (carfilzomib) U.S. prescribing information to include its use in combination with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.

"I am pleased that the addition of subcutaneous daratumumab to KYPROLIS plus dexamethasone will offer increased flexibility and convenience for patients with relapsed or refractory multiple myeloma and will greatly reduce the administration burden," said David M. Reese , M.D., executive vice president of Research and Development at Amgen.

Keep reading... Show less
Solarvest Web Site Launched in Hong Kong to Service South Easy Asia

Solarvest Web Site Launched in Hong Kong to Service South Easy Asia

(TheNewswire)

Solarvest BioEnergy Inc.

TheNewswire - December 1st 2021 Solarvest BioEnergy Inc. ("Solarvest" or the "Company") (TSXV:SVS)

Keep reading... Show less
BioHarvest Sciences Appoints Astronaut Chris Hadfield to the Board of Advisors

BioHarvest Sciences Appoints Astronaut Chris Hadfield to the Board of Advisors

Hadfield's expertise will lead BioHarvest's expanded focus to include space biology

BioHarvest Sciences Inc. ("BioHarvest" or the "Company") (CSE: BHSC) has appointed renowned astronaut Chris Hadfield to its board of advisors as part of a drive to leverage its biotech technology platform to provide essential nutrition and active ingredients for space exploration and potential new settlements in space.

Keep reading... Show less

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BMY, CTXS, HEPS and STNE

The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.

Bristol-Myers Squibb Company (BMY)
Class: Investors who received Contingent Value Rights ("CVRs") (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers' acquisition of Celgene on November 20, 2019
Lead Plaintiff Motion Deadline: December 6, 2021
MISLEADING PROSPECTUS
To learn more, visit https://kclasslaw.com/cases/securities/nyse-bmy/

Keep reading... Show less

AbbVie Submits Application for Risankizumab in Moderate to Severe Crohn's Disease to European Medicines Agency

ABBVie (NYSE:ABBV) today announced it has submitted an application to the European Medicines Agency (EMA) seeking approval for risankizumab (SKYRIZI ® 600 mg intravenous (IV) induction and 360 mg subcutaneous (SC) maintenance therapy), an interleukin-23 (IL-23) inhibitor, for the treatment of patients 16 years and older with moderate to severe active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy. The submission is supported by three pivotal Phase 3 studies, ADVANCE, MOTIVATE and FORTIFY. 1,2

"Patients with moderate to severe Crohn's disease live with challenging symptoms, such as persistent diarrhea and abdominal pain, impacting their quality of life," said Tom Hudson, senior vice president of research and development, chief scientific officer, AbbVie. "We look forward to working with the regulatory authorities and hope to offer risankizumab as a potential first-in-class treatment option for patients living with this disease."

Keep reading... Show less

SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, OWLT, PTON, ZG INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:

Bristol-Myers Squibb Company (BMY)
Class: Investors who received Contingent Value Rights ("CVRs") (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers' acquisition of Celgene on November 20, 2019
Lead Plaintiff Motion Deadline: December 6, 2021
MISLEADING PROSPECTUS
To learn more, visit https://claimsfiler.com/cases/nyse-bmy-3/

Keep reading... Show less

Top News

Related News